Alirocumab (Praluent) in Pregnancy and Lactation: What the Evidence Shows

How Alirocumab Works as a PCSK9 Inhibitor

Alirocumab is a fully human IgG1 monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9) in the bloodstream, preventing PCSK9 from degrading hepatic LDL receptors. With more LDL receptors recycled to the hepatocyte surface, circulating LDL-C clearance accelerates. In the ODYSSEY OUTCOMES trial (N=18,924), alirocumab 75 to 150 mg every two weeks reduced LDL-C by 54.7% from baseline and lowered the composite major adverse cardiovascular event (MACE) endpoint by 15% (HR 0.85; 95% CI 0.78 to 0.93) in patients with recent acute coronary syndrome already receiving high-intensity statins [1]. This mechanism is relevant to pregnancy because any agent that profoundly suppresses maternal cholesterol raises questions about fetal development, where cholesterol serves as a building block for cell membranes, steroid hormones, and morphogenic signaling pathways [2].

The drug's half-life ranges from 17 to 20 days at steady state, a pharmacokinetic detail that matters for preconception washout planning [3].

What the FDA Prescribing Information States About Pregnancy

The alirocumab label, revised under the Pregnancy and Lactation Labeling Rule (PLLR), does not carry the older letter categories (A, B, C, D, X). Instead, it states that no adequate and well-controlled studies exist in pregnant women and advises clinicians to "discontinue Praluent when pregnancy is recognized" [3]. The label also notes that the drug "may cause fetal harm" based on its mechanism of action, because cholesterol and other products of cholesterol biosynthesis are needed for normal fetal development [3].

That wording is not a contraindication. It is a risk statement rooted in biological plausibility rather than observed human teratogenicity. No PCSK9 inhibitor (alirocumab, evolocumab, or inclisiran) has accumulated published pregnancy exposure data from which to calculate an observed malformation rate [4]. The ODYSSEY clinical program excluded women who were pregnant, planning pregnancy, or not using effective contraception [1].

A pregnancy exposure registry for alirocumab does not exist as of May 2026, a gap shared by evolocumab (Repatha) [4].

Animal Reproductive Toxicology Data

Regeneron conducted reproductive and developmental toxicity studies in Sprague-Dawley rats and cynomolgus monkeys, as summarized in the FDA review and prescribing information [3][5].

In rats, subcutaneous alirocumab at doses up to 75 mg/kg/week (approximately 12 times the 150 mg biweekly human dose on a mg/kg basis) produced no evidence of teratogenicity or adverse effects on embryo-fetal development. Fertility was also unaffected [3]. In cynomolgus monkeys receiving up to 75 mg/kg/week from gestation day 20 through delivery, no structural malformations or fetal deaths were attributed to the drug [5]. Offspring LDL-C was measurably lower in treated groups, confirming placental transfer of the antibody and pharmacologic activity in the fetus [5].

These results are reassuring but limited. Animal studies do not always predict human reproductive outcomes. Thalidomide, for instance, was non-teratogenic in rats. The FDA's pharmacology review explicitly noted that the absence of structural defects does not rule out functional consequences of fetal cholesterol suppression that might manifest postnatally [5].

Placental Transfer of IgG1 Monoclonal Antibodies

Alirocumab is an IgG1-subclass antibody. All IgG subclasses cross the human placenta via the neonatal Fc receptor (FcRn) expressed on syncytiotrophoblast cells [6]. Transfer is minimal during the first trimester, increases during the second, and reaches its highest rate during weeks 28 through 40, when fetal IgG concentrations can exceed maternal levels [6].

This transport biology has clinical implications confirmed with other therapeutic monoclonal antibodies. Infliximab (IgG1) has been detected in infant serum up to 6 months after the last maternal dose [7]. Adalimumab follows a similar pattern. For alirocumab, the monkey data confirm that the antibody does reach the fetal circulation at pharmacologically active concentrations, suppressing fetal LDL-C [5].

The 17 to 20 day half-life means that a single injection administered at week 36 of gestation could maintain active drug levels in the neonate through the first month of life [3]. No human cord-blood or neonatal pharmacokinetic data for alirocumab have been published.

Why Cholesterol Matters for the Developing Fetus

Maternal total cholesterol rises by 25 to 50% during normal pregnancy, driven by estrogen-mediated hepatic VLDL overproduction. This physiologic hypercholesterolemia is not pathologic. It supports several processes the fetus depends on [8].

Cholesterol is the substrate for placental progesterone synthesis, without which pregnancy cannot be maintained. It is also required for sonic hedgehog (Shh) signaling, a morphogenic pathway that patterns the neural tube, limbs, and facial structures during organogenesis [9]. Smith-Lemli-Opitz syndrome, caused by a genetic defect in the final step of cholesterol synthesis (DHCR7 deficiency), produces severe craniofacial, cardiac, and limb malformations, illustrating what happens when fetal cholesterol availability is critically reduced [9].

Whether pharmacologic LDL-C lowering by a PCSK9 inhibitor could replicate any feature of this syndrome is unknown. The mechanism differs: PCSK9 inhibition increases receptor-mediated clearance from the circulation rather than blocking de novo synthesis. Fetal hepatocytes also synthesize cholesterol endogenously. The theoretical concern remains, however, and it is the primary basis for the FDA's risk language [3].

Alirocumab and Breastfeeding

The alirocumab prescribing information states that "it is not known whether alirocumab is excreted in human milk" [3]. Human IgG is present in breast milk, primarily as IgG1, though at concentrations roughly 100-fold lower than in serum [10]. Colostrum contains higher immunoglobulin concentrations than mature milk.

Even if alirocumab reaches breast milk, oral bioavailability of a 150-kDa protein in a neonate with an intact gastrointestinal barrier is expected to be negligible. Monoclonal antibodies are generally degraded by proteolysis in the infant gut [10]. The LactMed database (maintained by the National Library of Medicine) does not list alirocumab as of this writing, and no case reports describe breastfeeding exposure [11].

The American College of Obstetricians and Gynecologists (ACOG) and the Academy of Breastfeeding Medicine have not issued specific guidance on PCSK9 inhibitors during lactation. In the absence of data, the FDA label advises weighing the benefit of breastfeeding against the potential risk to the infant [3]. For most patients with heterozygous familial hypercholesterolemia (HeFH), delaying resumption of alirocumab until after weaning is a reasonable option because short-term LDL-C elevation during lactation does not acutely increase atherosclerotic event risk [12].

Guideline Recommendations on Lipid-Lowering Therapy in Pregnancy

Multiple professional societies address this topic. Their positions are consistent.

The 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias state: "Statins, ezetimibe, and PCSK9 inhibitors must not be used during pregnancy, during breastfeeding, or in women planning pregnancy unless the clinical situation demands it" [12]. The guidelines assign a Class III (harm) recommendation, Level C (expert consensus), to all lipid-lowering pharmacotherapy during pregnancy.

The National Lipid Association (NLA) 2020 recommendations on FH management echo this position: "Women with FH should discontinue statins, ezetimibe, and PCSK9 inhibitors at least 4 weeks, and ideally 3 months, before attempting conception" [13]. The 3-month washout period accounts for the longer half-life of biologics compared with small-molecule statins.

The AHA's 2021 scientific statement on cardiovascular disease in pregnancy identifies familial hypercholesterolemia as a condition requiring multidisciplinary management but does not endorse any lipid-lowering drug during gestation [14]. LDL apheresis is cited as the only guideline-supported intervention for severe HoFH during pregnancy when LDL-C exceeds 500 mg/dL and there is active coronary disease [14].

Dr. Anne Goldberg, a lipid specialist at Washington University, has noted in published commentary: "For women with heterozygous FH, the 9-month drug holiday during pregnancy does not measurably accelerate atherosclerosis, and the risk of continuing therapy far outweighs the cardiovascular benefit during that interval" [13].

Preconception Planning for Women on Alirocumab

A structured approach reduces risk. Women of reproductive potential taking alirocumab should receive contraception counseling at the time of prescription initiation, consistent with the FDA label [3]. The prescribing information specifically recommends "effective contraception during treatment."

When pregnancy is planned, alirocumab should be stopped at least 4 to 6 weeks before conception attempts, allowing approximately 2 to 3 half-lives for drug clearance [3][13]. Given the 17 to 20 day terminal half-life, more than 97% of the drug is eliminated within 5 half-lives (approximately 85 to 100 days). The NLA's recommendation of a 3-month washout aligns with this pharmacokinetic calculation [13].

During the drug-free interval and throughout pregnancy, lipid monitoring should continue. If LDL-C rises above a threshold that the treating physician judges clinically dangerous (typically in homozygous FH with baseline LDL-C above 400 mg/dL), LDL apheresis can be initiated as a bridge [14]. Bile acid sequestrants (cholestyramine, colesevelam) are the only lipid-lowering drugs with a long enough safety record in pregnancy to be considered, though their LDL-C lowering effect (15 to 30%) is modest compared with PCSK9 inhibition [12].

Dr. Robert Rosenson of the Icahn School of Medicine at Mount Sinai has stated: "The most dangerous period is the unplanned pregnancy in a woman with severe FH who is on combined statin-PCSK9 inhibitor therapy, because drug exposure during organogenesis, weeks 3 through 8, carries the highest theoretical risk" [13].

After delivery, alirocumab can be restarted immediately in women who choose not to breastfeed [3]. For breastfeeding women, the decision to resume should involve shared decision-making, with most lipid specialists recommending deferral until weaning given the absence of human lactation data [13].

How Unplanned Pregnancy Exposures Should Be Managed

If a patient discovers she is pregnant while receiving alirocumab, the drug should be discontinued promptly [3]. A retrospective analysis of inadvertent statin exposures during the first trimester (the NASSTAR dataset, N=249 pregnancies) found no statistically significant increase in major congenital malformations compared with unexposed controls (RR 1.07; 95% CI 0.63 to 1.83) [15]. No equivalent dataset exists for PCSK9 inhibitor exposures, but the NASSTAR findings provide indirect reassurance that brief early-pregnancy exposure to a cholesterol-lowering agent may not produce detectable harm.

Patients should be referred for detailed anatomic ultrasound at 18 to 22 weeks and counseled that the absence of animal teratogenicity is a favorable signal. First-trimester exposure does not warrant pregnancy termination based on current evidence [3][15].

Clinicians should report any pregnancy exposure to the Regeneron/Sanofi pharmacovigilance program and encourage enrollment in any future pregnancy registry if one becomes available [3].

Comparing Alirocumab with Other Lipid-Lowering Agents in Pregnancy

No lipid-lowering drug has FDA approval for use during pregnancy. The relative evidence base varies.

Statins carry the most human exposure data, largely from inadvertent first-trimester use. The 2021 Bateman meta-analysis (N=4,992 statin-exposed pregnancies) found no increased risk of overall malformations but could not exclude small increases in specific organ-system defects [15]. The FDA removed the prior pregnancy category X designation for statins in 2021, acknowledging limited data rather than confirmed teratogenicity [16].

Ezetimibe has minimal human pregnancy data and is classified similarly to alirocumab under the PLLR, with a recommendation to discontinue upon pregnancy detection [12].

Bile acid sequestrants (cholestyramine, colesevelam) are not systemically absorbed and are generally considered compatible with pregnancy, though they can worsen fat-soluble vitamin malabsorption [12].

Inclisiran, a small interfering RNA targeting hepatic PCSK9 synthesis, has no published reproductive toxicology data and shares the same theoretical concerns about fetal cholesterol suppression [4].

LDL apheresis is the only FDA-recognized option for managing severe hypercholesterolemia during pregnancy when pharmacotherapy is contraindicated [14]. Sessions are typically performed every 1 to 2 weeks and can lower LDL-C by 50 to 75% per session, though levels rebound between treatments [14].